Longeveron Inc. (LGVN) stock surged +1.71%, trading at $0.64 on NASDAQ, up from the previous close of $0.63. The stock opened at $0.64, fluctuating between $0.63 and $0.66 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 0.64 | 0.66 | 0.62 | 0.64 | 102.2K |
| Jul 07, 2026 | 0.65 | 0.67 | 0.63 | 0.63 | 85.88K |
| Jul 06, 2026 | 0.62 | 0.69 | 0.60 | 0.65 | 983.36K |
| Jul 02, 2026 | 0.72 | 0.75 | 0.68 | 0.69 | 362.86K |
| Jul 01, 2026 | 0.72 | 0.79 | 0.71 | 0.73 | 611.89K |
| Jun 30, 2026 | 0.73 | 0.75 | 0.69 | 0.70 | 387.2K |
| Jun 29, 2026 | 0.70 | 0.71 | 0.69 | 0.71 | 448.63K |
| Jun 26, 2026 | 0.73 | 0.75 | 0.70 | 0.72 | 300.66K |
| Jun 25, 2026 | 0.74 | 0.81 | 0.72 | 0.73 | 186K |
| Jun 24, 2026 | 0.82 | 0.82 | 0.74 | 0.74 | 256.7K |
| Jun 23, 2026 | 0.80 | 0.85 | 0.80 | 0.80 | 144.14K |
| Jun 22, 2026 | 0.84 | 0.85 | 0.80 | 0.80 | 391.24K |
| Jun 18, 2026 | 0.84 | 0.87 | 0.82 | 0.82 | 239.72K |
| Jun 17, 2026 | 0.77 | 0.85 | 0.76 | 0.84 | 302.86K |
| Jun 16, 2026 | 0.80 | 0.80 | 0.76 | 0.77 | 83.89K |
| Jun 15, 2026 | 0.82 | 0.82 | 0.78 | 0.79 | 163.84K |
| Jun 12, 2026 | 0.78 | 0.82 | 0.78 | 0.78 | 135.28K |
| Jun 11, 2026 | 0.76 | 0.80 | 0.75 | 0.77 | 228.26K |
| Jun 10, 2026 | 0.78 | 0.78 | 0.76 | 0.77 | 133.63K |
| Jun 09, 2026 | 0.75 | 0.78 | 0.74 | 0.77 | 119.74K |
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
| Employees | 25 |
| Beta | -0.38 |
| Sales or Revenue | $709.00K |
| 5Y Sales Change% | -0.757% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep